A PYMNTS Company

US: Impax faces drug delay antitrust suit

By  |  March 12, 2018

According to a report on Monday, March 12, Impax Laboratories went to trial over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication’s manufacturer.

Jury selection began in Boston federal court in a case centered on an alleged “pay-for-delay” settlement, in which a generic manufacturer agrees to resolve legal challenges to a brand-name drug’s patents and delay making a cheaper version.

The trial is one of a handful to have taken place since the US Supreme Court in 2013 said that such settlements, which also involve brand-name drug companies paying the generic manufacturers, can be found to be anticompetitive.

The case is being pursued by a class of consumers and third-party insurers and by several retailers, including CVS Health, Walgreens Boots Alliance Inc and Rite Aid.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.